French regulatory row casts long shadow over Europe
This article was originally published in SRA
Executive Summary
The radical reforms to France's drug agency Afssaps proposed in the wake of the Mediator drug affair have sent shock waves through the French regulatory and political establishment1. But the effects will be felt in other agencies and among policymakers, not to mention the pharmaceutical industry, across the EU.